Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study).
Bassetti M, Vena A, Giacobbe DR, Falcone M, Tiseo G, Giannella M, Pascale R, Meschiari M, Digaetano M, Oliva A, Rovelli C, Carannante N, Losito AR, Carbonara S, Mariani MF, Mastroianni A, Angarano G, Tumbarello M, Tascini C, Grossi P, Mastroianni CM, Mussini C, Viale P, Menichetti F, Viscoli C, Russo A; CEFTABUSE Study Group. Bassetti M, et al. Open Forum Infect Dis. 2020 Apr 21;7(5):ofaa139. doi: 10.1093/ofid/ofaa139. eCollection 2020 May. Open Forum Infect Dis. 2020. PMID: 32462046 Free PMC article.
BACKGROUND: Few data are reported in the literature about the outcome of patients with severe extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy. METHODS: A multicenter retros …
BACKGROUND: Few data are reported in the literature about the outcome of patients with severe extended-spectrum beta-lactamase-producing Ent …
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, Menichetti F, Mastroianni CM, Tumbarello M, Grossi P, Artioli S, Carannante N, Cipriani L, Coletto D, Russo A, Digaetano M, Losito AR, Peghin M, Capone A, Nicolè S, Vena A; CEFTABUSE Study Group. Bassetti M, et al. Int J Antimicrob Agents. 2019 Apr;53(4):408-415. doi: 10.1016/j.ijantimicag.2018.11.001. Epub 2018 Nov 8. Int J Antimicrob Agents. 2019. PMID: 30415002 Free article.
This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for different Pseudomonas aeruginosa infections. A retrospective study was performed at 22 hospitals in Italy (June 2016-March 2018). ...
This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for different Pseudomonas aeruginosa infectio …